Clinical Trial Update: Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial investigating sugemalimab as consolidation therapy after chemoradiation in limited-stage small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limited-stage Small Cell Lung Cancer

Drugs mentioned

• Sugemalimab (sugemalimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Limited Stage Small Cell Lung Cancer | Phase 2, Phase 3 | Status: RECRUITING